• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Karus Therapeutics - Articles and news items

hodgkin-lymphoma

Karus Therapeutics doses first lymphoma patients in Phase I KA2237 clinical study

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110β and p110δ. Inhibiting these two isoforms combines an immunotherapeutic response…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +